Mediwound Ltd (MDWD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Mediwound Ltd stock (MDWD) is currently trading at $16.61. Mediwound Ltd PS ratio (Price-to-Sales) is 12.85. Analyst consensus price target for MDWD is $31.33. WallStSmart rates MDWD as Sell.
- MDWD PE ratio analysis and historical PE chart
- MDWD PS ratio (Price-to-Sales) history and trend
- MDWD intrinsic value — DCF, Graham Number, EPV models
- MDWD stock price prediction 2025 2026 2027 2028 2029 2030
- MDWD fair value vs current price
- MDWD insider transactions and insider buying
- Is MDWD undervalued or overvalued?
- Mediwound Ltd financial analysis — revenue, earnings, cash flow
- MDWD Piotroski F-Score and Altman Z-Score
- MDWD analyst price target and Smart Rating
Mediwound
📊 No data available
Try selecting a different time range
Smart Analysis
Mediwound Ltd (MDWD) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Mediwound Ltd (MDWD) Key Strengths (1)
56.99% held by institutions, strong professional interest
Supporting Valuation Data
Mediwound Ltd (MDWD) Areas to Watch (8)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Revenue declining -68.00%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 12.8x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 5.0x book value
Supporting Valuation Data
Mediwound Ltd (MDWD) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 8.0/10) while 8 fall into concern territory (avg 1.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (12.85), Price/Book (4.99) suggest expensive pricing. Growth concerns include Revenue Growth at -68.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -63.90%, Operating Margin at -417.80%, Profit Margin at -140.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -63.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -68.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MDWD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MDWD's Price-to-Sales ratio of 12.85x trades at a deep discount to its historical average of 55.35x (58th percentile). The current valuation is 97% below its historical high of 513.41x set in Nov 2015, and 1818% above its historical low of 0.67x in Mar 2020. Over the past 12 months, the PS ratio has expanded from ~10.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Mediwound Ltd (MDWD) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Mediwound Ltd is in a turnaround phase, with management focused on restoring profitability. Revenue reached 17M with 68% decline year-over-year. The company is currently unprofitable, posting a -140.8% profit margin.
Key Findings
Spending 26% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 68% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -140.8% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Mediwound Ltd.
Bottom Line
Mediwound Ltd is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Mediwound Ltd(MDWD)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration. The company is headquartered in Yavne, Israel.